Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like ...

Viking expects to report data from the study in the second half of 2025. The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed to ...